Comparative Pharmacology
Head-to-head clinical analysis: LAZCLUZE versus SELARSDI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LAZCLUZE versus SELARSDI.
LAZCLUZE vs SELARSDI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LAZCLUZE (lazertinib) is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that irreversibly binds to and inhibits EGFR tyrosine kinase, including mutant forms with T790M resistance mutations and exon 19 deletions, thereby blocking downstream signaling pathways involved in tumor cell proliferation and survival.
Selective angiotensin II type 1 receptor antagonist that blocks vasoconstriction and aldosterone secretion.
20 mg orally once daily with or without food.
Intravenous 0.15 mg/kg every 8 hours for 14 days.
None Documented
None Documented
The terminal elimination half-life of Lazcluze is approximately 24-30 hours, supporting once-daily dosing with steady-state achieved within 5-7 days.
Terminal elimination half-life is approximately 11 hours (range 7–15 hours), supporting twice-daily dosing; half-life may be prolonged in renal impairment.
Lazcluze is primarily eliminated via biliary excretion into feces, with approximately 70-80% of the administered dose recovered as unchanged drug in feces. Renal elimination accounts for less than 10% of the dose, with less than 1% excreted unchanged in urine.
Primarily renal excretion of unchanged drug (approximately 70%) and glucuronide conjugate (approximately 20%); biliary/fecal elimination accounts for less than 10%.
Category C
Category C
Unknown
Unknown